BioSpace News Archive

CalciMedica Inc. (“CalciMedica” or the “Company), a clinical-stage biotechnology company targeting calcium release-activated calcium (CRAC) channels for the treatment of acute and severe inflammatory diseases, today announced data from a randomized, controlled, open-label clinical study showing substantially improved outcomes with Auxora™ (formerly called CM4620-IE) as a treatment for severe COVID-19 pneumonia.

- Worldwide sales of $7.3 billion in the second quarter, including $615 million of COVID-19 diagnostic testing-related sales - Growth rates in business areas initially most impacted by COVID-19 improved significantly over the course of the second quarter - Abbott continues to strengthen its portfolio with several recent regulatory approvals, including FreeStyle Libre 2, TriClip and Gallant heart devices [16-July-2020

Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announced the initiation of a prospective randomized control trial (RTC) utilizing Daxor’s BVA-100 (Blood Volume Analyzer, “BVA”) technology to guide volume treatment in heart failure patients.

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to announce that it has completed its clinical trial agreement with Westchester Research Center at Westchester General Hospital in Miami, Florida, for its multinational Phase 2b/3 human study of NP-120 (Ifenprodil) for COVID-19.

Clinical Trial Application approved in Russia for the Phase 2/3 study with opaganib in severe COVID-19 patients following recent approval in the UK and similar submission in Italy -- The Phase 2/3 study aims to enroll 270 subjects in up to 40 clinical sites; enrollment planned to be initiated later this month with potential submission of Emergency Use Authorization application planned for Q4/2020 -- In parallel, the U.S. Phase 2a study with opaganib in patients with severe COVID-19 is ad

Accelerate Diagnostics, Inc. announced today that management will host a conference call on Thursday, August 6, 2020 at 4:30 p.m. Eastern Time to review 2020 second quarter financial results. To listen

First Prospective Multi-Center Study Evaluating Same Day Discharge for Patients Undergoing Cardiac Ablation Procedures for Atrial Fibrillation

The Ibn Sina Foundation announced it is launching a second COVID-19 testing site, together with CVS Health, at its Ibn Sina North Shepherd Community Clinic location.

Biocept, Inc. announces that Institutional Shareholder Services and Glass Lewis & Co. both have recommended that stockholders vote in favor of Biocept’s proxy proposal to authorize a reverse stock split of Biocept’s common stock, as further described in Biocept’s Proxy Statement for its 2020 Annual Meeting of Stockholders.

Incyte announced that it has scheduled its second quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, August 4, 2020.